Efficacy of lasmiditan for the acute treatment of perimenstrual migraine

MacGregor, Anne; Komori, Mika; Krege, John H.; Baygani, Simin; Vincent, Maurice; Pavlović, Jelena; Igarashi, Hisaka

doi:10.1177/03331024221118929

Cited by 8 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figure 1 demonstrated the detail flowchart of the search and selection results. Five hundred sixteen potentially relevant articles were found through the initial search, and 7 RCTs were finally included for this meta-analysis 13,15–17,23–25 . The baseline characteristics of 7 included RCTs were shown in Table 1.…”

Section: Resultsmentioning

confidence: 99%

“…Five hundred sixteen potentially relevant articles were found through the initial search, and 7 RCTs were finally included for this meta-analysis. 13,[15][16][17][23][24][25] The baseline characteristics of 7 included RCTs were shown in Table 1. These studies were published between 2012 and 2022, and the total sample size was 6515.…”

Section: Literature Search Study Characteristics and Quality Assessmentmentioning

confidence: 99%

“…Among the eligible RCTs, 7 RCTs reported pain free at 2 hours, 13,[15][16][17][23][24][25] 5 RCTs reported pain free at 24 hours, 13,15,16,24,25 6 RCTs reported pain relief at 2 hours and MBS free at 2 hours, 13,[15][16][17]24,25 whereas 6 RCTs reported adverse events. 13,[15][16][17]23,25 Jadad scores of the 7 studies varied from 3 to 5, and thus all 7 studies had high quality based on the quality assessment.…”

Section: Literature Search Study Characteristics and Quality Assessmentmentioning

confidence: 99%

See 2 more Smart Citations

Exploration of Lasmiditan 200 mg Versus 100 mg for the Treatment of Migraine: A Meta-analysis Based on Aggregate Data

Wang,

Feng

2024

Clin Neuropharm

View full text Add to dashboard Cite

Objectives Lasmiditan holds important potential in treating migraine, but its ideal dose remains elusive. This meta-analysis is conducted based on aggregate data and aims to compare the efficacy of lasmiditan 200 mg versus 100 mg for acute treatment of migraine attack. Methods PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases were systematically searched, and we included the randomized controlled trials comparing the efficacy of lasmiditan 200 mg versus 100 mg for migraine patients. This meta-analysis was conducted using the random-effect model or fixed-effect model based on the heterogeneity. The primary outcome was pain free at 2 hours. Secondary outcomes included pain relief at 2 hours, pain free at 24 hours, most bothersome symptom free at 2 hours, and adverse events. Results Seven randomized controlled trials and 6515 patients were included in this meta-analysis. Compared with lasmiditan 100 mg for migraine patients, lasmiditan 200 mg was able to significantly improve pain free at 2 hours (odd ratio [OR], 1.28; 95% confidence interval [CI], 1.14–1.44; P < 0.0001) and pain free at 24 hours (OR, 1.35; 95% CI, 1.14–1.60; P = 0.0005), but showed no effect on pain relief at 2 hours (OR, 1.00; 95% CI, 0.90–1.12; P = 0.98) or most bothersome symptom free at 2 hours (OR, 0.93; 95% CI, 0.83–1.03; P = 0.17). Lasmiditan 200 mg was associated with the increase in adverse events compared with lasmiditan 100 mg (OR, 1.28; 95% CI, 1.15–1.43; P < 0.0001). Conclusions Lasmiditan 200 mg is more effective to improve pain free at 2 hours and 24 hours than lasmiditan 100 mg for the acute treatment of migraine patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Literature Search Study Characteristics and Quality Assessmentmentioning

confidence: 99%

Section: Literature Search Study Characteristics and Quality Assessmentmentioning

confidence: 99%

See 1 more Smart Citation

Exploration of Lasmiditan 200 mg Versus 100 mg for the Treatment of Migraine: A Meta-analysis Based on Aggregate Data

Wang,

Feng

2024

Clin Neuropharm

View full text Add to dashboard Cite

show abstract

“…Therefore, the use of triptans with NSAIDs remains a controversial issue. Moreover, a post-hoc analysis revealed that lasmiditan, a novel drug for migraine, achieved significant efficacy in 2-h pain freedom compared to placebo for perimenstrual migraine attacks [ 28 ]. This suggests that lasmiditan may also be a viable option for treating menstrual migraine.…”

Section: Discussionmentioning

confidence: 99%

Comparative efficacy of different treatments for menstrual migraine: a systematic review and network meta-analysis

Zhang

2023

J Headache Pain

View full text Add to dashboard Cite

Background Menstrual migraine is a subtype of migraine disease that is typically more disabling, longer-lasting, and more challenging to treat. The purpose of this network meta-analysis (NMA) is to compare the relative efficacy of treatments for menstrual migraine. Methods We systematically searched databases, including PubMed, EMBASE, and Cochrane, and included all eligible randomized controlled trials in the study. We conducted the statistical analysis using Stata version 14.0, based on the frequentist framework. We used the Cochrane Risk of Bias tool for randomized trials version 2 (RoB2) to assess the risk of bias of the included studies. Results This network meta-analysis included 14 randomized controlled trials with 4601 patients. For short-term prophylaxis, frovatriptan 2.5 mg twice daily had the highest probability of effectiveness [OR = 1.87 (95% CI: 1.48 to 2.38)] compared to placebo. For acute treatment, the results showed that sumatriptan 100 mg [OR = 4.32 (95% CI: 2.95 to 6.34)] was the most effective treatment compared to placebo. Conclusions These findings suggest that frovatriptan 2.5 mg twice daily was best for short-term prevention, sumatriptan 100 mg were best for acute treatment. More high-quality randomized trials are required to determine the most effective treatment.

show abstract

“…The authors cited small sample size as a probable reason for the lack of significance at lower doses, particularly the 50 mg dose (n = 24). 35…”

Section: Efficacy and Timingmentioning

confidence: 99%

Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy

Anderson¹,

VanderPluym²

2023

DDDT

View full text Add to dashboard Cite

Migraine is a common neurological disorder that is present in a large proportion of the global population. It is estimated to occur in around 20.7% of women and 10.7% of men in the United States. The pathophysiology of migraine is a major focus of research, and medications have been developed to interrupt the processes that generate headache and other bothersome symptoms of migraine attacks. The triptan class of medications acts as a direct agonist at the 5-HT1B/D receptor but its use is limited by contraindications for those with coronary or cerebrovascular disease. Lasmiditan is a first-in-class agonist at the 5-HT1F serotonin receptor that does not appear to generate vasoconstriction. This article reviews the design, development, and place in therapy for lasmiditan. A narrative review of the literature using the Ovid MEDLINE database was performed. The rationale behind the development of lasmiditan and pre-clinical, proof-of-concept, Phase II, pivotal, Phase III trials and post-hoc data is covered. Additionally, the efficacy and safety of lasmiditan when compared to other acute treatments in migraine is described, including lasmiditan's side effect profile and status as a Schedule V substance. Further, head-to-head studies of lasmiditan compared with other acute treatments are required.

show abstract

Efficacy of lasmiditan for the acute treatment of perimenstrual migraine

Cited by 8 publications

References 38 publications

Exploration of Lasmiditan 200 mg Versus 100 mg for the Treatment of Migraine: A Meta-analysis Based on Aggregate Data

Exploration of Lasmiditan 200 mg Versus 100 mg for the Treatment of Migraine: A Meta-analysis Based on Aggregate Data

Comparative efficacy of different treatments for menstrual migraine: a systematic review and network meta-analysis

Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy

Contact Info

Product

Resources

About